Scilex Holding Company (SCLX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Development of Non-Opioid Products	30.25M	56.59M	46.74M	38.03M	31.32M
Development of Non-Opioid Products Growth	-46.54%	21.07%	22.90%	21.45%	32.92%
Total	30.25M	56.59M	46.74M	38.03M	31.32M
Total Growth	-46.54%	21.07%	22.90%	21.45%	32.92%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
United States	30.25M	56.59M	46.74M	38.03M	31.32M
United States Growth	-46.54%	21.07%	22.90%	21.45%	32.92%
Total	30.25M	56.59M	46.74M	38.03M	31.32M
Total Growth	-46.54%	21.07%	22.90%	21.45%	32.92%

Data Source: S&P Global Market Intelligence Last updated: Apr 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 22, 2026

Data Sources Report a data error